Purdue Pharma Agrees to $5 Billion Penalty and Restructuring in DOJ Opioid Settlement

U.S. Department of Justice announced. From 2007 to 2017, Purdue Pharma unlawfully promoted its opioid products to hundreds of prescribers whom it had reason to suspect were issuing prescriptions without a legitimate medical purpose, according to the Department of Justice.

The company also misled the Drug Enforcement Administration about the effectiveness of its anti-diversion programs. In addition, Purdue Pharma relied on counts from questionable prescribers to support deceptive requests to increase production quotas. Purdue Pharma paid kickbacks to prescribers through its doctor speaker program, the Department of Justice stated.

The company also paid kickbacks to an electronic health record platform. ' He added, 'The company willfully rejected the law and ignored the diversion of their highly addictive prescription drugs. U.S. Purdue Pharma will operate as usual until May 1, 2026.

The company will permanently cease operations on May 1, 2026. Substantially all of Purdue Pharma’s assets will be transferred to Knoa Pharma LLC on May 1, 2026, according to Purdue Pharma.

Medicines distributed through Purdue Pharma will be distributed by Knoa Pharma after May 1, 2026. 4 billion settlement with opioid crisis victims and a bipartisan group of 15 states, Connecticut’s attorney general announced. U.S. District Judge Madeline Cox Arleo listened to nearly seven hours of testimony from individuals before approving the plea deal, CNBC reported.

More than 200 victims submitted letters describing personal experiences with opioid addiction and loss. Over 40 people delivered statements in court.